PMID- 12797499
OWN - NLM
STAT- MEDLINE
DCOM- 20031003
LR  - 20220309
IS  - 0903-1936 (Print)
IS  - 0903-1936 (Linking)
VI  - 21
IP  - 6
DP  - 2003 Jun
TI  - The early allergic response in small airways of human precision-cut lung slices.
PG  - 1024-32
AB  - To study the role of small airways in the early allergic response (EAR), the 
      method of human precision-cut lung slices (PCLS) was developed and used to 
      examine the bronchoconstriction elicited by passive sensitisation and allergen 
      provocation. Viable human PCLS of 250-microm thickness containing airways <1.5 mm 
      in outer diameter were prepared from lung lobes obtained from lung resection and 
      taken into culture. According to the low release of lactate dehydrogenase and the 
      constant ciliary beat frequency, human PCLS were viable for at least 3 days. 
      Following overnight passive sensitisation with serum from allergic individuals, 
      administration of grass-pollen extract or activating immunoglobulin E antibody 
      resulted in immediate airway contraction that was quantified by videomicroscopy. 
      The extent of the EAR increased with decreasing airway size (outer airway 
      diameter), with the strongest response occurring in the terminal bronchioles. 
      Histamine receptor antagonism was ineffective, and leukotriene or thromboxane 
      receptor antagonism attenuated the early allergic response only in some cases. 
      However, simultaneous blockade of leukotriene and thromboxane receptors almost 
      completely prevented the early allergic response in the precision-cut lung slices 
      from all individuals, suggesting such a dual treatment as a potential future 
      asthma therapy.
FAU - Wohlsen, A
AU  - Wohlsen A
AD  - Research Centre Borstel, Borstel, Germany.
FAU - Martin, C
AU  - Martin C
FAU - Vollmer, E
AU  - Vollmer E
FAU - Branscheid, D
AU  - Branscheid D
FAU - Magnussen, H
AU  - Magnussen H
FAU - Becker, W M
AU  - Becker WM
FAU - Lepp, U
AU  - Lepp U
FAU - Uhlig, S
AU  - Uhlig S
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
RN  - 0 (Acetates)
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Cyclopropanes)
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (Hydrazines)
RN  - 0 (Quinolines)
RN  - 0 (Sulfides)
RN  - 2L8T9S52QM (Triprolidine)
RN  - 88SD2J5ZNX (SQ 29548)
RN  - MHM278SD3E (montelukast)
SB  - IM
MH  - Acetates/pharmacology
MH  - Anti-Allergic Agents
MH  - Anti-Asthmatic Agents/pharmacology
MH  - Bridged Bicyclo Compounds, Heterocyclic
MH  - Bronchi/drug effects/*immunology/ultrastructure
MH  - *Bronchial Provocation Tests
MH  - Bronchoconstriction/drug effects/*immunology
MH  - Cilia/drug effects/immunology/ultrastructure
MH  - Culture Techniques/*methods
MH  - Cyclopropanes
MH  - Fatty Acids, Unsaturated
MH  - Humans
MH  - Hydrazines/pharmacology
MH  - Hypersensitivity/*immunology
MH  - *Immunization, Passive
MH  - Lung/drug effects/*immunology/ultrastructure
MH  - Quinolines/pharmacology
MH  - Reaction Time/drug effects/immunology
MH  - Sulfides
MH  - Time Factors
MH  - Triprolidine/pharmacology
EDAT- 2003/06/12 05:00
MHDA- 2003/10/04 05:00
CRDT- 2003/06/12 05:00
PHST- 2003/06/12 05:00 [pubmed]
PHST- 2003/10/04 05:00 [medline]
PHST- 2003/06/12 05:00 [entrez]
AID - 10.1183/09031936.03.00027502 [doi]
PST - ppublish
SO  - Eur Respir J. 2003 Jun;21(6):1024-32. doi: 10.1183/09031936.03.00027502.